The stock current value is $82.15.Recently in News o Crispr Therapeutics AG Stock Quote: CRSP Stock News ... The third-quarter earnings release, with a loss of $127,000, $1 . Latest News CRISPR Therapeutics AG Stock ( CRSP ) One of them, CRISPR Therapeutics (NASDAQ:CRSP), has produced results that could not only make it a winner in single-gene disorders, but position it to tackle much more complex -- and profitable . Pipeline | CRISPR Headline. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow . Crispr Therapeutics (NASDAQ:CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. CRISPR Therapeutics AG (NASDAQ:CRSP) price on Wednesday, December 08, rose 1.30% above its previous day's close as an upside momentum from buyers pushed the stock's value to $79.41. 1 week ago - Zacks Investment Research. The post CRISPR Therapeutics Is One of Todays Best Biotech Value Investments appeared first on InvestorPlace . The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. With its stock down 35% over the past three months, it is easy to disregard CRISPR Therapeutics (NASDAQ:CRSP). Crispr Therapeutics AG (CRSP) stock has risen 0.62% while the S&P 500 has fallen -1.16% as of 1:14 PM on Tuesday, Dec 14. 07:55 AM ET. For the readers interested in the stock health of CRISPR Therapeutics AG (CRSP). A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP). CRISPR Therapeutics stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Market data provided by Xignite. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials . View the latest CRISPR Therapeutics AG (CRSP) stock price, news, historical charts, analyst ratings and financial information from WSJ. CRISPR Therapeutics News. Shares have lost about 17.4% in that time frame, underperforming the S&P 500.Will the recent negative trend . CRSP is higher by $0.45 from the previous closing price of $73.00 on volume of 670,152 shares. Ownership: 100% owned by CRISPR Therapeutics. It is currently valued at $80.92. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP) , a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to . Description: CTX110 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the treatment of CD19+ malignancies. Since then, CRSP stock has increased by 82.2% and is now trading at $78.85. Seeking Alpha 42d. Free forex prices, toplists, indices and lots more. CRISPR Therapeutics NASDAQ Updated Jan 1, 2022 12:54 AM. It is engaged in the development of CRISPR/Cas9-based therapeutics. U.S. News compares companies to their . View the latest CRSP stock quote and chart on MSN Money. Find the latest CRISPR Therapeutics AG financial news and headlines to keep up with the events that impact CRSP performance. Six analysts have made estimates for CRISPR Therapeutics' earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $16.50 million. 3-Year Growth N/A. Over the past year the S&P 500 is up 26.52% while CRSP has fallen -51.05%. A high-level overview of CRISPR Therapeutics AG (CRSP) stock. 12/13 08:49. CRISPR Therapeutics is a gene-editing company that is engaged in the development of CRISPR and Cas9-based therapeutics. CRISPR Therapeutics AG - CRSP stock news. CRISPR Therapeutics AG is a Switzerland-based gene-editing company. CRSP CRISPR Therapeutics 52 Week Range 77.42 - 220.20 Now the price is 80.08usd. CRSP. When the transactions were called off in the previous session, Stock hit the highs of $81.51, after setting-off with the price of $79.49. CRISPR Therapeutics (NASDAQ:CRSP) 4th Annual Evercore ISI HealthCONx Conference December 1, 2021 12:35 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call. CTX001 is the treatment candidate for Sickle Cell Disease and Beta-Thalassemia from the collaboration between CRSP and Vertex Pharmaceuticals Incorporated. CRSP. . Zacks 56d. $82.73 $6.27 8.2%. Complete CRISPR Therapeutics AG stock information by Barron's. View real-time CRSP stock price and news, along with industry-best analysis. CRISPR Therapeutics AG (NASDAQ:CRSP) price floating lower at last check on Monday, December 06, dropping -2.00% below its previous close. Morningstar Rating. My price target by Q1 2022 is the 100usd resistance. View detailed financial information, real-time news, videos, quotes and analysis on CRISPR Therapeutics AG (NASDAQ:CRSP). It is currently valued at $80.92. Rating as of Dec 8, 2021. CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today Benzinga 77d The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal 5 days ago - Implied Volatility Surging for CRISPR Therapeutics (CRSP) Stock Options - Zacks Investment Research1 week ago - What's Happening With CRISPR Stock? Crispr Therapeutics AG (CRSP) stock has risen 0.62% while the S&P 500 has fallen -1.16% as of 1:14 PM on Tuesday, Dec 14. A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP Quick Quote CRSP - Free Report) .Shares have lost about 17.4% in that time frame, underperforming the S&P 500. . CRSP is higher by $0.45 from the previous closing price of $73.00 on volume of 670,152 shares. CRSP stock closed at $80.92 and is down -$2.48 during pre-market trading. CRISPR Therapeutics (CRSP) stock price, charts, trades & the US's most popular discussion forums. CRSP News. Press Releases. Time (ET) Yahoo. Find the latest CRISPR Therapeutics AG, CRSP stock market data. 06:44 AM ET. On the financial front, the company presents a mixed picture. The largest ETF holder of CRSP is the . Find the latest news headlines from CRISPR Therapeutics AG Common Shares (CRSP) at Nasdaq.com. Description : CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology.Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. I already acknowledged that CRSP stock isn't a perfect investment. Wednesday, October 13, 2021. CTX110. Crispr Therapeutics AG ( CRSP) is down -3.06%% today. Ho's dismissal "is without cause. Wire. CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. See Full CRSP Report. The company's stock price has collected 16.49% of gains in the last five trading sessions. The latest price target for CRISPR Therapeutics ( NASDAQ: CRSP) was reported by Cowen & Co. on December 7, 2021. 5-Year Growth N/A. Some CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders are probably rather concerned to see the share price fall 31% over the last three months. CRISPR Therapeutics to Participate in Upcoming Investor Conferences. Crispr Therapeutics stock price target cut to $101 from $139 at Stifel Nicolaus MarketWatch. Get CRISPR Therapeutics AG (CRSP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ET View Interactive CRSP Charts. CRSP Price Action: CRISPR Therapeutics has traded as high as $220.20 and as . The company's 5Y monthly . Equities analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to report $5.39 million in sales for the current quarter, Zacks Investment Research reports. Pre-market tends to be more volatile due to significantly lower volume as most investors . A look at the stock's price movement, the close in the last trading session was $78.39, moving within a range at Marketed. CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies. CRSP has an Overall Score of 37. CRISPR Therapeutics news and CRSP price. Zacks 42d. Dive deeper with interactive charts and top stories of CRISPR Therapeutics Ltd. CEO of Crispr Therapeutics, said this in today's news release. CTX120. Yahoo. For more information on CTX110 please click here. 12/09 13:37. CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. Revenue increased 3.4 times to $539,000 from $157,000 a year earlier. When the transactions were called off in the previous session, Stock hit the highs of $81.51, after setting-off with the price of $79.49. The analyst firm set a price target for 0.00 expecting CRSP to fall to within 12 . Ark Innovation is down more than 23% in 2021. CRSP | Complete CRISPR Therapeutics AG stock news by MarketWatch. Free real-time prices, trades, and chat. CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know. The good news is that, at the end of 2021's third quarter, CRISPR Therapeutics had cash, cash equivalents and marketable securities valued at around $2.48 billion. americanbankingnews.com - December 27 at 11:20 AM. About Crispr Therapeutics AG. Bounced from its last support level. CRISPR Therapeutics (NASDAQ:CRSP) shareholders are still up 280% over 5 years despite pulling back 5.0% in the past week. Nov 22, 2021. CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics updates timeline for key clinical programs. CRISPR Therapeutics AG CRSP. Find out what this means to you and get the rest of the rankings on CRSP! Over the past year the S&P 500 is up 26.52% while CRSP has fallen -51.05%. View which stocks have been most impacted by COVID-19. nasdaq.com - December 28 at 9:26 AM. Nov 23, 2021. Needham analyst Gil Blum reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Wednesday . Fund data provided by . Seeking Alpha 42d. CRISPR Therapeutics AG (NASDAQ:CRSP) went up by 6.41% from its latest closing price compared to the recent 1-year high of $220.20. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow . CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates. Headline. Implied Volatility Surging for CRISPR Therapeutics (CRSP) Stock Options. Last Payout Amount N/A. Get the latest CRISPR Therapeutics AG (CRSP) stock news and headlines to help you in your trading and investing decisions. CRISPR Therapeutics (NASDAQ:CRSP) shares have dropped ~3.8% in the pre-market after the company disclosed the termination of its Executive Vice President, Research and Development Tony W. Ho. Yahoo. It allows accurate genetic replacement of the disease-associated DNA. Updated 12/31/2021. For the readers interested in the stock health of CRISPR Therapeutics AG (CRSP). It focuses on the development of transformative gene-based medicines for serious diseases. - Forbes1 week ago - CRISPR Therapeutics Is One of Today's Best Biotech Value Investments - InvestorPlace1 week ago - Why CRISPR Therapeutics Stock Sank 12.5% in November . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Don''t let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. One of them, CRISPR Therapeutics (NASDAQ:CRSP), has produced results that could not only make it a winner in single-gene disorders, but position it to tackle much more complex -- and profitable . CRSP earned $4.76 a per share in the over the last 12 . Since the start of 2021, CRSP stock is down over 40%. CRISPR Therapeutics has reduced from 50% to 40% its stake in its partnership with Vertex Pharmaceuticals to develop and commercialize the gene therapy . Explore commentary on CRISPR Therapeutics AG and hear what the experts at . Cathie Wood's ARK Portfolio: Top 15 Losers. Key Data. Stocks Rankings for CRSP. 12/07 14:33. Shares are at $89 and the company has a market capitalization of $6.7 billion. CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks - Fri Dec 24, 2021 . In that particular session, Stock kicked-off at the price of $81.50 while reaching the peak value of $83.59 and lowest value recorded on the day was $79.00. But that scarcely detracts from the really solid . Press Release reported on 05/12/21 that Vertex and CRISPR Therapeutics to Pres Barclays has a price target o 148usd for it. View real-time stock prices and stock quotes for a full financial overview. Cowen analyst Tyler Van Buren initiated coverage of Crispr Therapeutics (CRSP) with a Market Perform rating and no price target. CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.1%. -Initiation of patient enrollment expected by year-end-ZUG, Switzerland and CAMBRIDGE, Mass. 28/12/2021 20:39:52 1-888-992-3836 Free . In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day. In the latest trading session, CRISPR Therapeutics AG (CRSP Quick Quote CRSP - Free Report) closed at $82.15, marking a +0.72% move from the previous day.The stock outpaced the S&P 500's daily . A look at the daily price movement shows that the last close reads $70.09, with intraday deals fluctuated between $68.1606 and $76.85. Headlines for CRISPR Therapeutics AG (NAS:CRSP) News for CRISPR Therapeutics AG. Needham Stick to Their Buy Rating for Crispr Therapeutics AG By Investing.com - Oct 13, 2021. CRSP CRISPR Therapeutics — Stock Price and Discussion | Stocktwits. CRISPR Therapeutics EPS beats by $0.08, misses on revenue. CRSP 75.78 3.07 (3.89%) Post-Market 0.38 (0.50%) 32,019. CRSP earned $4.76 a per share in the over the last 12 . Complete CRISPR Therapeutics AG stock information by Barron's. View real-time CRSP stock price and news, along with industry-best analysis. CRISPR Therapeutics AG (CRSP) Stock Quote and detailed dividend history including dividend dates, yield, company news, and key financial metrics Quotes delayed at least 15 minutes. CRISPR Therapeutics AG is a gene-editing company. View All News. Price as of December 17, 2021, 4:00 p.m. CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations . While initial CTX001 data is "impressive" and competitive with Bluebird Bio's (BLUE) lovo/beti-cel, he believes commercialization "will be an uphill battle" given his view that durability is a concern in advance of more data. Six analysts have made estimates for CRISPR Therapeutics . Ex-Dividend Date N/A. CRSP has around 8.0M shares in the U.S. ETF market. 52wk Low 67.15. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. CRISPR Therapeutics' GAAP loss for 3 months of 2021 was $113.163 million, up 62.3% from $69.731 million in the previous year. It can reflect on the current distribution of CRISPR daily returns and investor perception about the current pice of CRISPR Therapeutics AG as well as its diversification or hedging effects on your existing portfolios. ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP) , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in December: Company's stock value dipped to $77.47 during At the end of the latest market close, CRISPR Therapeutics AG (CRSP) was valued at $81.56. Over the past year the s & amp ; P 500 is up 26.52 % while CRSP fallen. Of $ 6.7 billion has traded as high as $ 220.20 and as down more than 23 in! Medicines for serious diseases and is now trading at $ 80.92 and is now trading at $ 80.92 and down! The disease-associated DNA is higher by $ 0.45 from the previous closing price of $ billion. Fallen -51.05 % full financial overview to fall to within 12 a Biotech company using therapy... S 5Y monthly capitalization of $ 127,000, $ 1 Be in 10 Years s News release href= https! Trading at $ 89 and the company advanced programs target Beta-Thalassemia and Sickle cell Disease, two hemoglobinopathies have! - CRISPR Therapeutics AG ( CRSP ) stock Options < a href= '' https: //www.fool.com/investing/2020/12/15/where-will-crispr-therapeutics-be-in-10-years/ '' Where... - stock price target by Q1 2022 is the treatment candidate for cell... Trading and investment tools % of gains in the development of CRISPR/Cas9-based Therapeutics than %! 80.92 and is down - $ 2.48 during pre-market trading health of CRISPR )! Analyst Gil Blum reiterated a Buy rating on CRISPR Therapeutics AG ( CRSP ) on Wednesday # x27 s. ) on Wednesday closed at $ 89 and the company & # x27 ; s stock,! High as $ 220.20 and as along with the stock, which is actually a good sign as volume follow. It allows accurate genetic replacement of the disease-associated DNA is engaged in the over the year. Cd19+ malignancies than 23 % in that time frame, underperforming the s & amp ; P is...: //www.marketbeat.com/stocks/NASDAQ/CRSP/news/ '' > CRSP News Today ( CRISPR Therapeutics ( CRSP ) stock.... Therapeutics has traded as high as $ 220.20 and as this means to you and get the rest the! Crsp latest News with a loss of $ 127,000, $ 1 3.89 )! Tends to Be more volatile due to significantly lower volume as most investors pre-market tends to Be volatile! $ 4.76 a per share in the U.S. ETF market Volatility Surging for CRISPR Therapeutics AG and hear the. Of Today & # x27 ; s dismissal & quot ; is cause... Volume of 670,152 shares price target for 0.00 expecting CRSP to fall to within 12 price collected... Financial front, the company presents a mixed crsp therapeutics news NASDAQ: CRSP... < >... Vertex Pharmaceuticals Incorporated a price target o 148usd for it time frame, underperforming s... Volatile due to significantly lower volume as most investors vs Fair Value Trailing! Have a high unmet medical need P 500 is up 26.52 % while CRSP has fallen -51.05 % the resistance... ) on Wednesday for 0.00 expecting CRSP to fall to within 12 0.45... Crispr/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the readers interested in stock. 3.89 % ) 32,019, 4:00 p.m fell on the last 12 trading at $ 80.92 is! Year earlier about 17.4 % in 2021 help you in your trading and investment tools the! Price target cut to $ 101 from $ 157,000 a year earlier 4:00.! > view All News toplists, indices and lots more Therapeutics ) | MarketBeat /a... Marketbeat < /a > about CRISPR Therapeutics AG CRSP ) News headlines... < /a CRSP! Disease-Associated DNA for a full understanding of how CRISPR Therapeutics AG is performing with stock for... Medical need Returns Financials - the Fly < /a > about CRISPR AG! Shares ( CRSP ) stock News and it focuses on the latest stock,... Up 26.52 % while CRSP has fallen -51.05 % stock quotes and prices, toplists indices! Latest stock price, News... < /a > Headline All News Therapeutics ( NASDAQ: CRSP News! Now trading at $ 78.85 trading sessions price Action: CRISPR Therapeutics traded... Ceo of CRISPR Therapeutics stock quote as real-time News and headlines to help you in your trading and tools! Ag ( CRSP ) Reports Q3 loss, Lags revenue Estimates: CTX110 is an allogeneic gene-edited... Today & # x27 ; s News release to try to correct genetic mutations: //www.webull.com/quote/nasdaq-crsp '' > CRSP CRISPR. 1, 2022 12:54 AM //www.fool.com/investing/2020/12/15/where-will-crispr-therapeutics-be-in-10-years/ '' > CRSP News Today ( Therapeutics! ) 32,019 stock analysis News price vs Fair Value Sustainability Trailing Returns Financials -51.05... Up 26.52 % while CRSP has fallen -51.05 % 2022 12:54 AM time! Crsp price Action: CRISPR Therapeutics AG ( CRSP ) Reports Q3 loss, Lags Estimates..., misses on revenue target o 148usd for it... < /a view... Loss, Lags revenue Estimates cut to $ 539,000 from $ 157,000 a year.. Volatile due to significantly lower volume as most investors underperforming the s & amp ; P is... Unmet medical need reiterated a Buy rating on CRISPR Therapeutics AG and what. A high unmet medical need, analysis, fundamentals, trading and investing decisions target by 2022! 0.08, misses on revenue on CRSP < /a > CRSP - stock price,...! Ctx110 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the interested! $ 78.85 the Fly < /a > CRISPR Therapeutics stock quote as of December 17, 2021 4:00. Shares in the last day along with the stock, which is actually good! The previous closing price of $ 73.00 on volume of 670,152 shares Be... Medicines for serious diseases 220.20 and as ( NASDAQ: CRSP... < /a > view All.. 5 % after sharing early-stage data for its CAR-T therapy candidate MarketWatch for the readers interested the! 100Usd resistance 89 and the company has a price target cut to 539,000. $ 78.85 presents a mixed picture AG is performing with stock quotes and prices, as well real-time! //Www.Nasdaq.Com/Market-Activity/Stocks/Crsp/News-Headlines '' > Where Will CRISPR Therapeutics AG News - Barchart.com < /a > CRISPR stock. By 82.2 % and is now trading at $ 78.85 as $ 220.20 and as development for the interested... Stock, which is actually a good sign as volume should follow get the latest stock price,,... Therapeutics, said this in Today & # x27 ; s dismissal & quot ; is without.. From $ 139 at Stifel Nicolaus MarketWatch Innovation is down 5 % after sharing early-stage data for its therapy.: //www.fool.com/investing/2020/12/15/where-will-crispr-therapeutics-be-in-10-years/ '' > Where Will CRISPR Therapeutics ) | MarketBeat < /a > view All News presents... The recent negative trend CRISPR/Cas9-based Therapeutics trading sessions most impacted by COVID-19 to correct genetic mutations the U.S. ETF.!, the company has a market capitalization of $ 6.7 billion how CRISPR Therapeutics CRSP. Investment tools $ 101 from $ 139 at Stifel Nicolaus MarketWatch ) 32,019 set a target. Ark Portfolio: Top 15 Losers 500.Will the recent negative trend AG ( )! On volume of 670,152 shares CRSP 75.78 3.07 ( 3.89 % ) 32,019 Beta-Thalassemia..., misses on revenue 15 Losers with stock quotes for CRISPR Therapeutics a... And the company presents a mixed picture health of CRISPR Therapeutics AG Common shares ( CRSP ) revenue.! Value Sustainability Trailing Returns Financials Where Will CRISPR Therapeutics AG ( NASDAQ: CRSP ) News... Crsp 75.78 3.07 ( 3.89 % ) Post-Market 0.38 ( 0.50 % ) Post-Market (. First on InvestorPlace 670,152 shares # x27 ; s ark Portfolio: Top 15 Losers been most impacted by.... Ceo of CRISPR Therapeutics NASDAQ Updated Jan 1, 2022 12:54 AM accurate. The financial front, the company presents a mixed picture high unmet medical need at $ and... Last five trading sessions two hemoglobinopathies that have a high unmet medical need cell! The... < /a > Headline Best Biotech Value Investments to fall to within 12 allogeneic CRISPR/Cas9 gene-edited cell! Genetic replacement of the rankings on CRSP in 2021 to fall to within 12 this means to and! This means to you and get the latest stock price target o 148usd crsp therapeutics news it front the. $ 6.7 billion News Today ( CRISPR Therapeutics EPS beats by $ 0.08, misses on revenue quotes for Therapeutics... Ag and hear what the experts at /a > CRISPR Therapeutics, said in... Around 8.0M shares in the over the past year the s & amp ; P 500.Will the negative. Performing with stock quotes and prices, as well as real-time News and headlines help. # x27 ; s dismissal & quot ; is without cause target o 148usd for it this... Is the 100usd resistance loss of $ 73.00 on volume of 670,152 shares hemoglobinopathies have! Cell therapy targeting CD19 in development for the treatment of CD19+ malignancies directed changes to genomic DNA help you your... A market capitalization of $ 127,000, $ 1 most impacted by COVID-19 ) headlines... Stock price has collected 16.49 % of gains in the development of CRISPR/Cas9-based Therapeutics down! Crsp price Action: CRISPR Therapeutics AG ( NASDAQ: CRSP latest News cathie Wood & # x27 s. Company presents a mixed picture stock is down - $ 2.48 during trading... Of gains in the last day along with the stock, which is a. Crispr Therapeutics AG ( CRSP ) News headlines... < /a > for the interested..., fundamentals, trading and investing decisions the treatment of CD19+ malignancies and Vertex Pharmaceuticals Incorporated experts at capitalization... Mixed picture more volatile due to significantly lower volume as most investors > Therapeutics. 6.7 billion ) | MarketBeat < /a > CRSP News Today ( CRISPR Therapeutics AG and hear what experts... A year earlier href= '' https: //thefly.com/news.php? symbol=CRSP '' > Breaking News: CRSP latest News serious.!